Exhibit 99.1

Exhibit 99.1

MANAGEMENT'S DISCUSSION AND ANALYSIS
(in US dollars)

This Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as at and for the three months ended March 31, 2017 and 2016. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This MD&A is dated May 15, 2017. All amounts in this report are in U.S. dollars, unless otherwise noted.

Except as otherwise indicated, all financial information contained in this MD&A and in the unaudited condensed interim Consolidated Financial Statements has been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The unaudited condensed interim Consolidated Financial Statements and this MD&A were reviewed by the Corporation’s Audit Committee and were approved by our Board of Directors.

Additional information about the Corporation can be obtained on EDGAR at www.sec.gov or on SEDAR at www.sedar.com.

Overview

Corporate Profile

Nymox Pharmaceutical Corporation is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. Since 1989, the Corporation’s activities and resources have been directed primarily on developing certain pharmaceutical technologies. Since 2002, Nymox has been developing its novel proprietary drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (“BPH”). NX-1207 showed positive results for the treatment of BPH in Phase 1 and 2 clinical trials in the U.S. and in follow-up studies of available subjects from the completed clinical trials. In 2009, Nymox started two pivotal double blind placebo controlled Phase 3 trials for NX-1207, NX02-0017 and NX02-0018, that were conducted at investigational sites across the U.S. with a total enrollment of approximately 1,000 patients. Nymox also initiated subsequent open-label U.S. re-injection Phase 3 safety studies, NX02-0020 and NX02-0022. The NX02-0017 study completed patient enrollment and participation in December 2013 and the NX02-0018 study in May 2014. Top-line results of the Phase 3 NX02-0017 and NX02-0018 U.S. clinical trials of NX-1207 for BPH at 12 months post-treatment were not statistically significant compared to placebo.

The Corporation is in the process of further data analysis and assessments of the two studies, and expects to continue its efforts to work on the development program. Nymox is also developing NX-1207 for the treatment of low-grade localized prostate cancer. A Phase 2 study of NX-1207 for low grade localized prostate cancer was started in 2012 with positive results reported in 2014. The Corporation is in the process of working towards definitive studies for this indication. The Corporation also has an extensive patent portfolio covering its marketed products, its investigational drug as well as other therapeutic and diagnostic indications. Nymox developed the AlzheimAlert™ test, which is certified with a CE Mark in Europe. Nymox developed and markets NicAlert™ and TobacAlert™;

which are tests that use urine or saliva to detect use of and exposure to tobacco products. NicAlert™ has received clearance from the FDA and is also certified with a CE Markin Europe. TobacAlert™ is the first test of its kind to accurately measure second and third hand smoke exposure in individuals.

During the second half of 2015, the Corporation has filed an F-3 Registration Statement made effective on August 4, 2015. The Company plans to utilize proceeds from the F-3 registration along with private placements and other types of financings, collaboration agreements, and revenues from product sales to fund its operations and research programs. In order to achieve its business plan and the realization of its assets and liabilities in the normal course of operations, the Corporation anticipates the need to raise additional debt or capital in the near term and/or achieve sales and other revenue-generating activities. Management has taken steps to reduce expenditures going forward in the short term by staff reductions, deferral of management salaries, and operational changes.

The top-line failure of the two Phase 3 studies of NX-1207 for BPH materially affects the Corporation’s current ability to fund its operations, meet its cash flow requirements, realize its assets and discharge its obligations. Management believes that current cash balances as of March 31, 2016 and anticipated funds from product sales are not sufficient to fund substantially all of its planned business operations and research and development programs over the next year. The Corporation intends to access financing through other sources of capital in order to fund these operations and activities over the next year.

We have incurred operating losses throughout our history. Management believes that such operating losses will continue for at least the next few years as a result of expenditures relating to research and development of our potential therapeutic products.

On July 27, 2015 Nymox announced initial clinical results from its ongoing analysis and assessment of its Phase 3 development program in BPH. The Company announced that the U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH had successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo. Fexapotide showed an excellent safety profile with no evidence of drug-related short-term or long-term toxicity nor any significant related molecular side effects in the 2 studies. As a result of the clinical benefits observed in the long-term extension trial, the Company announced that it intends to meet with regulatory authorities in various jurisdictions around the world and in due course explore the possibility to proceed to file for approval where possible.

Forward Looking Statements

Certain statements included in this MD&A may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities legislation and regulations, and are subject to important risks, uncertainties and assumptions. This forward-looking information includes amongst others, information with respect to our objectives and the strategies to achieve these objectives, as well as information with respect to our beliefs, plans, expectations, anticipations, estimates and intentions. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “plan”, “foresee”, “believe” or “continue” or the negatives of these terms or variations of them or similar terminology. We refer you to the Corporation’s filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, and of our Form 20-F, for a discussion of the various factors that may affect the Corporation’s future results. The results or events predicted in such forward-looking information may differ materially from actual results or events.

Results of Operations


Three Months Ended March 31	2017	2016
Total revenues	$78,394	$41,501
Net loss	$(2,813,703)	$(3,325,260)


Loss per share (basic & diluted)		$(0.06)			$(0.08)

Results of Operations – Q1 2017 compared to Q1 2016

Net loss was $2,813,703, or $0.06 per share, for the quarter ended March 31, 2017, compared to net loss of $3,325,260, or $0.08 per share, for the quarter ended March 31, 2016. The decrease in net losses for the three months ended March 31, 2017 compared to the same period in 2016 is primarily due to stock compensation charges of $1,532,053 in 2017 compared to $2,478,225 in 2016. The weighted average number of common shares outstanding for the three months ended March 31, 2017 was 49,702,744 compared to 43,984,573 for the same period in 2016.

Revenues

Revenues from sales of goods amounted to $78,394 for the quarter ended March 31, 2017, compared with $41,501 for the quarter ended March 31, 2016.

Research and Development

Research and development expenditures were $1,676,340 for the quarter ended March 31, 2017, compared with $1,695,085 for the quarter ended March 31,2016. Research and development expenditures mainly include costs incurred in advancing Nymox’s BPH product candidate NX-1207 through clinical trials, as well as costs related to its R&D pipeline. Research and development expenditures also include stock compensation charges of $748,226 in the three months ended March 31, 2017 and $1,237,805 in the comparative period in 2016.

Marketing Expenses

Marketing expenditures were $227 for the quarter ended March 31, 2017, compared with $2,606 for the quarter ended March 31, 2016. The Corporation expects that marketing expenditures will increase if and when new products are launched on the market.

General and Administrative Expenses

General and administrative expenses were $1,118,879 for the quarter ended March 31, 2017, compared with $1,560,005 for the quarter ended March 31, 2016. General and administrative expenditures also include stock compensation charges of $783,827 for the three months ended March 31, 2017 and $1,240,420 in the comparative period in 2016. The decrease of $441,126 for the quarter ended March 31, 2017 is mainly attributable to a decrease of $456,593 in stock compensation compared to 2016. The Corporation expects that general and administrative expenditures will increase as new product development leads to expanded operations.

Finance costs

Net finance costs were $51,470 for the quarter ended March 31, 2017, compared with net finance costs of $58,335 for the quarter ended March 31, 2016. An amount of $54,888 for the quarter ended March 31, 2017 represents accretion of debt discount incurred in connection with the convertible notes.

The Corporation incurs expenses in the local currency of the countries in which it operates, which include the United States, Canada and the Bahamas. Foreign exchange fluctuations had no meaningful impact on the Corporation’s results in 2017 or 2016.

Inflation

The Corporation does not believe that inflation has had a significant impact on its results of operations.

Contractual Obligations

Nymox has no contractual obligations of significance other than its accounts payable, accrued liabilities and the following:


Contractual Obligations	Total	Less than 1 year	1-3 years	4-5 years
Rent for laboratory and office space	$148,023	$123,636	$24,387	$0
Insurance premium installments	$0	$0	$0	$0
Operating leases	$4,823	$4,823	$0	$0
Convertible notes	$1,070,000	$1,070,000	$0	$0
Interest and fees on convertible notes	$57,067	$57,067	$0	$0
Total Contractual Obligations other than accounts payable and accrued liabilities	$1,279,913	$1,255,526	$24,387	$0

The redeemable preferred shares for the Corporation’s subsidiary Serex, Inc. in the amount of $400,000 have no specific terms of repayment.

Off-Balance Sheet Arrangements

The Corporation has no binding commitments for the purchase of property, equipment or intellectual property. The Corporation has no commitments that are not reflected in the statement of financial position except for operating leases and insurance premium installments.

Transactions with Related Parties

The Corporation had no transactions with related parties in 2017 and 2016 other than those disclosed for key management personnel in note 9 of the unaudited condensed interim Consolidated Financial Statements.

Financial Position

Liquidity, Capital Resources

As of March 31,2017, cash and receivables including tax credits receivable totaled $1,648,825 compared with $2,027,346 at December 31, 2016. The decrease is mainly due to cash used for general and administrative purposes and to support the preparation of the regulatory submissions of Fexapotide.

On January 18, 2017, the Company received cash from the exercise of warrants issued in connection with a private placement of common stock in early 2015. The Company received total proceeds of $103,810 and 51,905 shares were issued.

On March 9, 2017, the Company received cash from the exercise of warrants issued in conncection with a private placement of common stock in early 2015. The Company received total proceeds of $250,000 and 125,000 shares were issued.

The Company has incurred substantial operating losses since its inception due in large part to expenditures for its research and development activities as well as expense charges related to the issuance of stock options to key employees. As at March 31, 2017, we had an accumulated deficit of $133,904,253, and we have negative cash flows

from operations. The Corporation’s working capital deficiency was $223,851 at March 31, 2017. Our current level of annual expenditures continues to exceed the anticipated revenues from sales of goods and will therefore have to be covered by additional sources of funds.

In response to the top-line twelve month failure of the two Phase 3 trials of NX-1207 for BPH, Management has implemented steps to reduce expenditures, including staff reductions for the U.S. BPH development program for NX-1207, deferral of management salaries, and other operational changes. While management believes the use of the going concern assumption is appropriate, there is no assurance the above actions will be successful. The Condensed Unaudited Interim Consolidated Financial Statements for the three months ended March 31, 2017, do not include any adjustments or disclosures that may be necessary should the Corporation not be able to continue as a going concern. If the going concern assumption should not prove to be appropriate for the Condensed Unaudited Interim Consolidated Financial Statements for the three months ended March 31, 2017, then material adjustments to the carrying value, classification of assets and liabilities and reported results of operations may become necessary.

Capital disclosures

The Corporation's objective in managing capital is to ensure a sufficient liquidity position to finance its research and development activities, general and administrative expenses, working capital and overall capital expenditures, including those associated with patents. The Corporation makes every attempt to manage its liquidity to minimize shareholder dilution when possible.

In February 2016, the Corporation filed a prospectus supplement and accompanying prospectus related to the potential issuance and sale of up to $12,000,000 of our common stock, no par value per share, from time to time through our sales agent, Chardan Capital Markets, LLC, or Chardan. These sales, if any, will be made under an equity distribution agreement, dated February 5, 2016, between the Corporation and Chardan, which we refer to as the equity distribution agreement.

Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made by any method permitted by law deemed to be an “at-the-market” offering as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on The NASDAQ Capital Market, on any other existing trading market for our common stock or to or through a market maker or through an electronic communications network. If expressly authorized by us, Chardan may also sell our common stock in privately negotiated transactions. Chardan will act as sales agent on a commercially reasonable efforts basis, consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of NASDAQ. There is no specific date on which the offering will end, there are no minimum sale requirements and there are no arrangements to place any of the proceeds of this offering in an escrow, trust or similar account.

The capital management objectives remain the same as for the previous fiscal year. When possible, the Corporation tries to optimize its liquidity needs by non-dilutive sources, including sales, collaboration agreements, research tax credits and interest income. The Corporation's general policy on dividends is to retain cash to keep funds available to finance its research and development and operating expenses.

The Corporation is not subject to any capital requirements imposed by external parties other than the Nasdaq Capital Market requirements related to the Listing Rules.

Disclosure Controls and Procedures

Disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed is accumulated and communicated to senior management on a timely basis so that appropriate decisions can be made regarding public disclosure. The Corporation’s Chief Executive Officer and its Chief Financial Officer are responsible for establishing and maintaining disclosure controls and procedures. They are assisted in this

responsibility by the Corporation’s audit committee. Based on an evaluation of the Corporation’s disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934 and National Instrument 52-109), the Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures were not effective as of March,31 2017 because of the material weakness in our internal control over financial reporting that is described in our 2016 annual filings and reproduced below in “Management’s Annual Report on Internal Control Over Financial Reporting.”

The Corporation did not employ a sufficient complement of finance and accounting personnel at March 31, 2017 to ensure that there was proper segregation of incompatible duties related to certain processes, primarily impacting the expenditures/disbursements processes and information technology general controls (“ITGC”), and sufficient compensating controls did not exist in these areas. Specifically, because of the limited number of qualified personnel, review controls of expenditures and disbursements were not effective to ensure that expenditures and disbursements were properly authorized and recorded in the financial information system, and certain ITGCs that potentially impact two applications used for expenditures and disbursements were not effective to monitor activities of individuals with access to modify data.

Remediation Plan for Material Weaknesses in Internal Control over Financial Reporting

Management believes that a lack of segregation of duties is typical of companies with limited personnel and resources. Nonetheless, in response to the material weakness identified above, the Corporation, in the immediate future, intends to develop a plan with oversight from the Audit Committee of the Board of Directors to remediate the material weakness.

The remediation efforts expected to be implemented include the following:

Evaluate staffing levels and responsibilities to enhance appropriate segregation of duties where possible amongst our personnel. Establishing a more comprehensive review and approval process for authorizing user access to financial information systems and monitoring user access to ensure that all information technology controls designed to restrict access to applications and data are operating in a manner that provides the Corporation with assurance that such access is properly restricted to the appropriate personnel.

Changes in Internal Controls over Financial Reporting

Since December 31, 2016, we have made the following changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting: we have engaged an outside financial reporting expert on a contract basis to assist with external financial reporting matters under the supervision and review our CFO and audit committee.

NYMOX PHARMACEUTICAL CORPORATION
Consolidated Financial Statements
(Unaudited)

Financial Statements

Consolidated Statements of Financial Position as of March31, 2017 and December 31,2016 (Unaudited)

Consolidated Statements of Operations (Unaudited)

Consolidated Statements of Changes in Equity (Unaudited)

Consolidated Statements of Cash Flows (Unaudited)

Notes to Condensed Interim Consolidated Financial Statements


1.	Basis of preparation	14
2.	Liquidity, going concern and management's response	14
3.	Share capital	14
4.	Earnings per share	17
5.	Related party transactions	17
6.	Subsequent events	18

NYMOX PHARMACEUTICAL CORPORATION
Consolidated Statements of Financial Position (Unaudited)
March 31, 2017 and December 31, 2016
(in US dollars)


			March 31,		December 31,
Assets	Note		2017		2016
Current assets
Cash		$	1,632,385	$	2,017,660
Accounts receivable			14,750		6,421
Other receivables			1,690		3,265
Research tax credits receivable			0		0
Security deposit			7,487		7,487
Prepaid expenses			30,685		685
Inventories			1,245		2,590

Total current assets			1,688,242		2,038,108
Non-current assets
Property and equipment			1,461		1,749
Security deposit			17,396		17,396
Total assets		$	1,707,099	$	2,057,253
Liabilities and Stockholders’ Equity (Deficit)
Current liabilities
Accounts payable and accrued liabilities		$	1,912,093	$	1,367,845
Total current liabilities			1,912,093		1,367,845
Non-current liabilities
Convertible notes	4		964,266		930,828
Total liabilities			2,876,359		2,298,673
Stockholders’ Equity (Deficit)
Share capital – unlimited authorized shares at no par value 50,449,696 and 49,115,518 shares outstanding at March 31, 2017 and December 31, 2016, respectively			93,320,784		92,125,364
Share capital subscription receivable			(717,998 )		0
Additional paid-in capital			39,332,207		37,923,766
Accumulated deficit			(133,104,253 )		(130,290,550 )

Total stockholders’ equity (deficit)			(1,169,260 )		(241,420 )

Total liabilities, equity and stockholders’ equity (deficit)		$	1,707,099	$	2,057,253

See accompanying notes to the unaudited consolidated financial statements.

NYMOX PHARMACEUTICAL CORPORATION
Consolidated Statements of Operations (Unaudited)
Three month periods ended March 31, 2017 and 2016
(in US dollars)


		Three months ended
		March 31,
		2017		2016
Revenues
Sales of goods	$	78,394	$	41,501
Licensing revenues: Upfront payment		–		–
Total revenues		78,394		41,501

Operating expenses
Research and development		1,676,340		1,695,085
General and administrative		1,118,879		1,560,005
Marketing		227		2,606
Cost of sales		45,181		50,730
Total expenses		2,840,627		3,308,426

Loss from operations		(2,762,223 )		(3,266,925 )
Net finance costs		(51,470 )		(58,335 )

Net loss	$	(2,813,703 )	$	(3,325,260 )

Net loss per share Basic & Diluted	$	(0.06 )	$	(0.08 )

Weighted average number of common shares outstanding Basic & Diluted		49,702,744		43,984,573

See accompanying notes to the unaudited consolidated financial statements.

NYMOX PHARMACEUTICAL CORPORATION
Consolidated Statements of Changes in Equity (Unaudited)
Three-month periods ended March 31, 2017
(in US dollars)


					Share
					capital		Additional				Total
					Subscripti		paid-in				equity
	Number		Dollars		on		capital		Deficit		(Deficit)
Balance, December 31, 2016	49,115,518	$	92,125,364	$	–	$	37,923,766	$	(130,290,550)	$	(241,420)
Transactions with owners, recorded directly in equity:
Issuance of units	574,178		1,159,820		(717,998)		(88,012)		–		353,810
Stock-based compensation	760,000		35,600		–		1,496,453		–		1,532,053
Total contributions by owners	1,334,178		1,195,420		(717,998)		1,408,441		–		1,885,863
Net loss	–		–		–		–		(2,813,703)		(2,813,703)
Balance, March 31, 2017	50,449,696	$	93,320,784	$	(717,998)	$	39,332,207	$	(133,104,253)	$	(1,169,260)

See accompanying notes to the unaudited consolidated financial statements

NYMOX PHARMACEUTICAL CORPORATION
Consolidated Statements of Cash Flows (Unaudited)
Three-month periods ended March 31, 2017 and 2016
(in US dollars)


		2017		2016
Cash flows used in operating activities
Net loss	$	(2,813,703 )	$	(3,325,260 )
Adjustments for:
Depreciation of property and equipment		288		711
Stock-based compensation		1,532,053		2,478,225
Accretion expense		33,438		26,595
Changes in non-cash operating balances:
Accounts receivable and other receivables		(6,753 )		(5,966 )
Research tax credits receivable		-		144,043
Security deposit		-		-
Prepaid expenses		(30,000 )		(30,000 )
Inventories		1,345		24,935
Accounts payable and accrued liabilities		544,247		(956,622 )
Deferred revenue		-		-

Net cash flows used in operating activities		(739,085 )		(1,643,339 )

Cash flows from (used in) financing activities
Proceeds from issuance of share capital		-		2,100,000
Warrants Excise		353,810		-

Net cash flows provided by financing activities		353,810		2,100,000

Cash flows used in investing activities
Additions to property and equipment		-		-

Net (decrease) increase in cash		(385,275 )		456,661

Cash, beginning of the period		2,017,660		374,463
Cash, end of the period	$	1,632,385	$	831,124

See accompanying notes to the unaudited consolidated financial statements.

NYMOX PHARMACEUTICAL CORPORATION

Notes to Unaudited Consolidated Financial Statements

(in US dollars)

1.	Basis of preparation:

(a)

Statement of compliance:

The condensed unaudited interim consolidated financial statements of the Corporation have been prepared in accordance with International Financial Reporting Standards (“IFRS”) and its interpretations as issued by the International Accounting Standards Board (“IASB”) and in accordance with IAS 34, Interim Financial Reporting. The condensed unaudited interim consolidated financial statements do not include all of the information required for full annual financial statements and accordingly should be read in connection with the previously issued annual financial statements of the Corporation as at and for the year ended December 31, 2016.

The condensed interim consolidated financial statements were authorized for issuance by the Board of Directors on May 15, 2017.

(b)

Basis of measurement:

The condensed unaudited interim consolidated financial statements have been prepared on a going concern and on the historical cost basis. The functional currency of the Corporation is the US dollar.

2.	Liquidity, Going Concern and Managements Response

Management believes that current cash balances as at March 31, 2017 and anticipated funds from product sales are not sufficient to fund substantially all of its planned business operations and research and development programs over the next year. The Corporation intends to access financing through other sources of capital in order to fund these operations and activities over the next year.

The Corporation will have to seek other sources of financing in order to be able to pay its obligations as they become due, which could have an impact on its ability to continue as a going concern. Considering recent developments and the need for additional financing, there exists a material uncertainty that casts substantial doubt about the Corporation’s ability to continue as a going concern. These financial statements do not reflect adjustments that would be necessary if the going concern assumption was not appropriate. If the going concern assumption is not appropriate, then adjustments may be necessary to the carrying value and classification of assets and liabilities and reported results of operations and such adjustments could be material.

3.	Share capital:

The holders of common shares are entitled to receive dividends as declared, which is at the discretion of the Corporation, and are entitled to one vote per share at the annual general meeting of the Corporation. The Corporation has never paid any dividends.

(a)

Private placements:

In the first quarter of 2017, the Corporation completed two private placements of warrant excise for a total of $353,810. A total of 176,905 common shares were issued at an average price of $2.00 per share

(b)

Stock options:

NYMOX PHARMACEUTICAL CORPORATION

Notes to Unaudited Consolidated Financial Statements

(in US dollars)

The Corporation has established a stock option plan (the “Plan”) for its key employees, its officers and directors, and certain consultants. The Plan is administered by the Board of Directors of the Corporation. The Board may from time to time designate individuals to whom options to purchase common shares of the Corporation may be granted, the number of shares to be optioned to each, and the option price per share. The option price per share cannot involve a discount to the market price at the time the option is granted. The maximum number of shares which may be optioned under the stock option plan is 7,500,000. The maximum number of shares which may be optioned to any one individual is 15% of the total issued and outstanding common shares. Options under the Plan expire ten years after the grant date and vest either immediately or over periods up to six years, and are equity-settled. As of March 31, 2017, 4,128,000 options could still be granted by the Corporation.

The following table provides the activity of stock option awards during the three-month period ended March 31, 2017 and for options outstanding and exercisable at the end of the three-month period ended March 31, 2017, the weighted average exercise price and the weighted average years to expiration.


		Options outstanding
				Weighted
			Weighted	average
			average	remaining
			exercise	contractual
	Number		Price	life (in years)
Outstanding, December 31, 2016	3,372,000	$	5.78	6.67
Expired	–		–
Cancelled	–		–
Granted	–		–
Outstanding, March 31, 2017	3,372,000	$	5.78	6.42
Options exercisable	3,372,000	$	5.78	6.42

(c)

Stock-based compensation:


		Three months
		ended March 31,
Employee expenses		2017		2016
Stock options granted in 2011		–		–
Stock options granted in 2012		–		2,615
Stock options granted in 2014		–		–
Stock options granted in 2015		1,496,453		2,475,610
Stock options granted in 2016		–		–
Stock options granted in 2017		35,600		–
Total stock-based compensation expense recognized	$	1,532,053	$	2,478,225	$

(c)

Stock-based compensation (continued):

The stock-based compensation expense is disaggregated in the statements of operations and comprehensive loss as follows:

NYMOX PHARMACEUTICAL CORPORATION

Notes to Unaudited Consolidated Financial Statements

(in US dollars)


		Three months
		ended March 31,
		2017		2016
Stock-based
compensation pertaining to
general and administrative	$	783,827	$	1,240,420
Stock-based
compensation pertaining to
research and development		748,226		1,237,805

Total	$	1,532,053	$	2,478,225

No options were granted during the three-month period ended March 31, 2017 (2016 – none granted).

(d)

Warrants:


	Warrants outstanding
					Weighted
				Weighted	average
				average	remaining
				exercise	contractual
		Number		price	life (in years)
Outstanding, December 31, 2016		548,529	$	1.72	1.31
Exercised		548,529		1.72	-
Granted		-		-	-
Expired		-		-	-
Cancelled		-		-	-
Outstanding, March 31, 2017		-	$	-	-

On December 16, 2014, in connection with the convertible notes private placement financing referred to in note 6, the Corporation issued 107,000 warrants to the placement agent as partial consideration for the placement fees. Each warrant entitles the holder to acquire one common share of the Corporation at an exercise price of $0.54 prior to December 16, 2017. These warrants were excised during the first quarter of 2017.

NYMOX PHARMACEUTICAL CORPORATION

Notes to Unaudited Consolidated Financial Statements

(in US dollars)

4.	Earnings per share:

Weighted average number of common shares outstanding:


	Three months
	ended March 31,,
	2017	2016
Issued common shares at beginning of period	49,115,518	42,988,419
Effect of shares issued	587,226	996,154
Weighted average number of common shares outstanding - basic	49,702,744	43,984,573
Weighted average number of shares outstanding – diluted	49,702,744	43,984,573

Executive officers and directors participate in the Corporation’s stock option plan. Certain executive officer is covered under the corporation’s health plan.

Key management personnel compensation is comprised of:


		Three months
		ended March 31,
		2017		2016
Salaries	$	-	$	-
Short-term employee benefits		465		448
Stock-based compensation		1,496,453		2,475,610
	$	1,496,918	$	2,476,058

Total honorariums to the independent directors of the Corporation for participating in Board and Committee meetings were nil for the period ended March 31, 2017 (2016 – nil).

6.	Subsequent events:

The corporation has determined there are no subsequent events except below:

On May 3, 2017, the Company has filed to seek approval for marketing authorization for Fexapotide Triflutate in five European countries, comprising the Netherlands, the UK, Germany, France and Spain. This first filing for Fexapotide Triflutate is for the indication of treatment of the symptoms of BPH (benign prostatic hyperplasia; prostate enlargement).